BookR: School of Health Core Facilities Booking
PubMed Publications| Keyword search (4,163 papers available) |  |
"Soucy JP" Authored Publications:
| Title | Authors | PubMed ID | |
|---|---|---|---|
| 1 | Associations between brain and cognitive resilience, tau load and extent in Alzheimer's disease | Mitchell SW; Chan T; Trudel L; Hosseini SA; Macedo AC; Gonçalves MP; Rahmouni N; Hall BJ; Socualaya KMQ; Therriault J; Servaes S; Bezgin G; Zheng Y; Aumont E; Wang YT; Arias JF; Real APB; Jia WL; Hopewell R; Hsiao C; Soucy JP; Vitali P; Pascoal TA; Rosa-Neto P; | 41512332 PERFORM |
| 2 | Alzheimer s Imaging Consortium | Mitchell SW; Chan T; Trudel L; Hosseini SA; Macedo AC; Gonçalves MP; Rahmouni N; Hall BJ; Socualaya KMQ; Therriault J; Servaes S; Bezgin G; Zheng Y; Aumont E; Wang YT; Arias JF; Real APB; Jia WL; Hopewell R; Hsiao C; Soucy JP; Vitali P; Pascoal TA; Rosa-Neto P; | 41433447 PERFORM |
| 3 | The PREVENT-AD cohort: Accelerating Alzheimer s disease research and treatment in Canada and beyond | Villeneuve S; Poirier J; Breitner JCS; Tremblay-Mercier J; Remz J; Raoult JM; Yakoub Y; Gallego-Rudolf J; Qiu T; Fajardo Valdez A; Mohammediyan B; Javanray M; Metz A; Sanami S; Ourry V; Wearn A; Pastor-Bernier A; Edde M; Gonneaud J; Strikwerda-Brown C; Tardif CL; Gauthier CJ; Descoteaux M; Dadar M; Vachon-Presseau É; Baril AA; Ducharme S; Montembeault M; Geddes MR; Soucy JP; Rajah N; Laforce R; Bocti C; Davatzikos C; Bellec L; Rosa-Neto P; Baillet S; Evans AC; Collins DL; Chakravarty MM; Blennow K; Zetterbe | 41020412 SOH |
| 4 | The PREVENT-AD cohort: accelerating Alzheimer s disease research and treatment in Canada and beyond | Villeneuve S; Poirier J; Breitner JCS; Tremblay-Mercier J; Remz J; Raoult JM; Yakoub Y; Gallego-Rudolf J; Qiu T; Valdez AF; Mohammediyan B; Javanray M; Metz A; Sanami S; Ourry V; Wearn A; Pastor-Bernier A; Edde M; Gonneaud J; Strikwerda-Brown C; Tardif CL; Gauthier CJ; Descoteaux M; Dadar M; Vachon-Presseau É; Baril AA; Ducharme S; Montembeault M; Geddes MR; Soucy JP; Rajah N; Laforce R; Bocti C; Davatzikos C; Bellec L; Rosa-Neto P; Baillet S; Evans AC; Collins DL; Chakravarty MM; Blennow K; Zetterberg H; S | 40778177 PSYCHOLOGY |
| 5 | Use of lecanemab and donanemab in the Canadian healthcare system: Evidence, challenges, and areas for future research | Smith EE; Phillips NA; Feldman HH; Borrie M; Ganesh A; Henri-Bhargava A; Desmarais P; Frank A; Badhwar A; Barlow L; Bartha R; Best S; Bethell J; Bhangu J; Black SE; Bocti C; Bronskill SE; Burhan AM; Calon F; Camicioli R; Campbell B; Collins DL; Dadar M; DeMarco ML; Ducharme S; Duchesne S; Einstein G; Fisk JD; Gawryluk JR; Grossman L; Ismail Z; Itzhak I; Joshi M; Harrison A; Kroger E; Kumar S; Laforce R; Lanctot KL; Lau M; Lee L; Masellis M; Massoud F; Mitchell SB; Montero-Odasso M; Myers Barnett K; Nygaard HB; Pasternak SH; Peters J; Rajah MN; Robillard JM; Rockwood K; Rosa-Neto P; Seitz DP; Soucy JP; Trenaman SC; Wellington CL; Zadem A; Chertkow H; | 39893139 CONCORDIA |
| 6 | Alzheimer's Imaging Consortium | Soucy JP; Belasso CJ; Cai Z; Bezgin G; Stevenson J; Rahmouni N; Tissot C; Lussier FZ; Rosa-Neto P; Rivaz HJ; Benali H; | 39782975 CONCORDIA |
| 7 | Biomarkers | Soucy JP; Belasso CJ; Cai Z; Bezgin G; Stevenson J; Rahmouni N; Tissot C; Lussier FZ; Rosa-Neto P; Rivaz HJ; Benali H; | 39784152 CONCORDIA |
| 8 | Brain PET Imaging in Small Animals: Tracer Formulation, Data Acquisition, Image Reconstruction, and Data Analysis | Bdair H; Kang MS; Ottoy J; Aliaga A; Kunach P; Singleton TA; Blinder S; Soucy JP; Leyton M; Rosa-Neto P; Kostikov A; | 38006502 PERFORM |
| 9 | Increased brain cholinergic innervation in isolated REM sleep behaviour disorder from prodromal multiple system atrophy | Wickens RH; Postuma RB; de Villers-Sidani É; Pelletier A; Blinder S; Gagnon JF; Soucy JP; Montplaisir J; Bedard MA; | 37939636 PERFORM |
| 10 | Bayesian workflow for the investigation of hierarchical classification models from tau-PET and structural MRI data across the Alzheimer's disease spectrum | Belasso CJ; Cai Z; Bezgin G; Pascoal T; Stevenson J; Rahmouni N; Tissot C; Lussier F; Rosa-Neto P; Soucy JP; Rivaz H; Benali H; | 37920382 PERFORM |
| 11 | Dosimetry of [18F]TRACK, the first PET tracer for imaging of TrkB/C receptors in humans | Thiel A; Kostikov A; Ahn H; Daoud Y; Soucy JP; Blinder S; Jaworski C; Wängler C; Wängler B; Juengling F; Enger SA; Schirrmacher R; | 37870640 PERFORM |
| 12 | Lactate's behavioral switch in the brain: An in-silico model | Soltanzadeh M; Blanchard S; Soucy JP; Benali H; | 37865309 PERFORM |
| 13 | A person with frontotemporal dementia shows increased metabolic rate across multiple brain regions after a series of tDCS sessions | Roncero C; Nikelski J; Soucy JP; Lahiri D; Seixas-Lima B; Chertkow H; | 37182684 PERFORM |
| 14 | Primary and Secondary Progressive Aphasia in Posterior Cortical Atrophy | Brodeur C; Belley É; Deschênes LM; Enriquez-Rosas A; Hubert M; Guimond A; Bilodeau J; Soucy JP; Macoir J; | 35629330 IMAGING |
| 15 | Radiosynthesis and In Vivo Evaluation of Four Positron Emission Tomography Tracer Candidates for Imaging of Melatonin Receptors | Bdair H; Singleton TA; Ross K; Jolly D; Kang MS; Aliaga A; Tuznik M; Kaur T; Yous S; Soucy JP; Massarweh G; Scott PJH; Koeppe R; Spadoni G; Bedini A; Rudko DA; Gobbi G; Benkelfat C; Rosa-Neto P; Brooks AF; Kostikov A; | 35420022 PERFORM |
| 16 | Normal cognition in Parkinson's disease may involve hippocampal cholinergic compensation: An exploratory PET imaging study with [(18)F]-FEOBV | Legault-Denis C; Aghourian M; Soucy JP; Rosa-Neto P; Dagher A; Aumont E; Wickens R; Bedard MA; | 34628195 PERFORM |
| 17 | CCCDTD5: Clinical role of neuroimaging and liquid biomarkers in patients with cognitive impairment | Brisson M; Brodeur C; Létourneau-Guillon L; Masellis M; Stoessl J; Tamm A; Zukotynski K; Ismail Z; Gauthier S; Rosa-Neto P; Soucy JP; | 33532543 PERFORM |
| 18 | Large-scale mGluR5 network abnormalities linked to epilepsy duration in focal cortical dysplasia. | DuBois JM, Mathotaarachchi S, Rousset OG, Sziklas V, Sepulcre J, Guiot MC, Hall JA, Massarweh G, Soucy JP, Rosa-Neto P, Kobayashi E | 33401137 PERFORM |
| 19 | Recommendations of the 5th Canadian Consensus Conference on the diagnosis and treatment of dementia. | Ismail Z, Black SE, Camicioli R, Chertkow H, Herrmann N, Laforce R, Montero-Odasso M, Rockwood K, Rosa-Neto P, Seitz D, Sivananthan S, Smith EE, Soucy JP, Vedel I, Gauthier S, CCCDTD5 participants | 32725777 PERFORM |
| 20 | Topographical distribution of Aβ predicts progression to dementia in Aβ positive mild cognitive impairment | Pascoal TA, Therriault J, Mathotaarachchi S, Kang MS, Shin M, Benedet AL, Chamoun M, Tissot C, Lussier F, Mohaddes S, Soucy JP, Massarweh G, Gauthier S, Rosa-Neto P, | 32582834 PERFORM |
| 21 | Chronic Neuroleptic-Induced Parkinsonism Examined with Positron Emission Tomography. | Galoppin M, Berroir P, Soucy JP, Suzuki Y, Lavigne GJ, Gagnon JF, Montplaisir JY, Stip E, Blanchet PJ | 32353194 PERFORM |
| 22 | Non-invasive in vivo hyperspectral imaging of the retina for potential biomarker use in Alzheimer's disease. | Hadoux X, Hui F, Lim JKH, Masters CL, Pébay A, Chevalier S, Ha J, Loi S, Fowler CJ, Rowe C, Villemagne VL, Taylor EN, Fluke C, Soucy JP, Lesage F, Sylvestre JP, Rosa-Neto P, Mathotaarachchi S, Gauthier S, Nasreddine ZS, Arbour JD, Rhéaume MA, Beaulieu S, Dirani M, Nguyen CTO, Bui BV, Williamson R, Crowston JG, van Wijngaarden P | 31530809 PERFORM |
| 23 | Development of "[11C]kits" for a fast, efficient and reliable production of carbon-11 labeled radiopharmaceuticals for Positron Emission Tomography. | Jolly D, Hopewell R, Kovacevic M, Li QY, Soucy JP, Kostikov A | 28038410 PERFORM |
| 24 | Brain perfusion during rapid-eye-movement sleep successfully identifies amnestic mild cognitive impairment. | Brayet P, Petit D, Baril AA, Gosselin N, Gagnon JF, Soucy JP, Gauthier S, Kergoat MJ, Carrier J, Rouleau I, Montplaisir J | 28522082 PERFORM |
| 25 | Brain cholinergic alterations in idiopathic REM sleep behaviour disorder: a PET imaging study with 18F-FEOBV. | Bedard MA, Aghourian M, Legault-Denis C, Postuma RB, Soucy JP, Gagnon JF, Pelletier A, Montplaisir J | 31078078 PERFORM |
| 26 | Dopamine cross-sensitization between psychostimulant drugs and stress in healthy male volunteers. | Booij L, Welfeld K, Leyton M, Dagher A, Boileau I, Sibon I, Baker GB, Diksic M, Soucy JP, Pruessner JC, Cawley-Fiset E, Casey KF, Benkelfat C | 26905412 PSYCHOLOGY |
| 27 | Metabotropic Glutamate Receptor Type 5 (mGluR5) Cortical Abnormalities in Focal Cortical Dysplasia Identified In Vivo With [11C]ABP688 Positron-Emission Tomography (PET) Imaging. | DuBois JM, Rousset OG, Guiot MC, Hall JA, Reader AJ, Soucy JP, Rosa-Neto P, Kobayashi E | 27578494 PERFORM |
| 28 | Biomarkers, designs, and interpretations of resting-state fMRI in translational pharmacological research: A review of state-of-the-Art, challenges, and opportunities for studying brain chemistry. | Khalili-Mahani N, Rombouts SA, van Osch MJ, Duff EP, Carbonell F, Nickerson LD, Becerra L, Dahan A, Evans AC, Soucy JP, Wise R, Zijdenbos AP, van Gerven JM | 28145075 PERFORM |
| 29 | Quantification of brain cholinergic denervation in Alzheimer's disease using PET imaging with [18F]-FEOBV. | Aghourian M, Legault-Denis C, Soucy JP, Rosa-Neto P, Gauthier S, Kostikov A, Gravel P, Bédard MA | 28894304 PERFORM |
| 30 | Altered Regional Cerebral Blood Flow in Idiopathic Hypersomnia. | Boucetta S, Montplaisir J, Zadra A, Lachapelle F, Soucy JP, Gravel P, Dang-Vu TT | 28958044 PERFORM |
| 31 | Amyloid and tau signatures of brain metabolic decline in preclinical Alzheimer's disease. | Pascoal TA, Mathotaarachchi S, Shin M, Park AY, Mohades S, Benedet AL, Kang MS, Massarweh G, Soucy JP, Gauthier S, Rosa-Neto P, Alzheimer’s Disease Neuroimaging Initiative | 29396637 PERFORM |
| 32 | Altered brain perfusion patterns in wakefulness and slow-wave sleep in sleepwalkers. | Desjardins MÈ, Baril AA, Soucy JP, Dang-Vu TT, Desautels A, Petit D, Montplaisir J, Zadra A | 29514303 PERFORM |
| 33 | Impaired sensorimotor processing during complex gait precedes behavioral changes in middle-aged adults. | Mitchell T, Starrs F, Soucy JP, Thiel A, Paquette C | 30247510 PERFORM |
| Title: | The PREVENT-AD cohort: Accelerating Alzheimer s disease research and treatment in Canada and beyond | ||||
| Authors: | Villeneuve S, Poirier J, Breitner JCS, Tremblay-Mercier J, Remz J, Raoult JM, Yakoub Y, Gallego-Rudolf J, Qiu T, Fajardo Valdez A, Mohammediyan B, Javanray M, Metz A, Sanami S, Ourry V, Wearn A, Pastor-Bernier A, Edde M, Gonneaud J, Strikwerda-Brown C, Tardif CL, Gauthier CJ, Descoteaux M, Dadar M, Vachon-Presseau É, Baril AA, Ducharme S, Montembeault M, Geddes MR, Soucy JP, Rajah N, Laforce R, Bocti C, Davatzikos C, Bellec L, Rosa-Neto P, Baillet S, Evans AC, Collins DL, Chakravarty MM, Blennow K, Zetterbe | ||||
| Link: | https://pubmed.ncbi.nlm.nih.gov/41020412/ | ||||
| DOI: | 10.1002/alz.70653 | ||||
| Publication: | Alzheimer s & dementia : the journal of the Alzheimer s Association | ||||
| Keywords: | biomarkers; clinical progression; cognition; data repository; neuroimaging; preclinical; | ||||
| PMID: | 41020412 | Category: | Date Added: | 2025-09-29 | |
| Dept Affiliation: |
SOH
1 StoP-AD Centre, Douglas Mental Health University Institute, McGill University, Montréal, Quebec, Canada. 2 Department of Psychiatry, McGill University, Montréal, Quebec, Canada. 3 McConnell Brain Imaging Center, Montreal Neurological Institute, McGill University, Montréal, Quebec, Canada. 4 Cerebral Imaging Centre, Douglas Mental Health University Institute, McGill University, Montréal, Quebec, Canada. 5 Integrated Program in Neuroscience, McGill University, Montréal, Quebec, Canada. 6 Research Center of the CIUSSS-NIM, Hôpital du Sacré-Coeur de Montréal, Montreal, Quebec, Canada. 7 Department of Medicine, Faculty of Medicine, Université de Montréal, Montréal, Quebec, Canada. 8 Department of Physics, Concordia University, Montréal, Quebec, Canada. 9 Department of Neurology and Neurosurgery, McGill University, Montréal, Quebec, Canada. 10 Faculté des sciences, Département d'informatique, Université de Sherbrooke, Sherbrooke, Quebec, Canada. 11 Normandie Univ, UNICAEN, INSERM, U1237, PhIND "Physiopathology and Imaging of Neurological Disorders", NeuroPresage Team, GIP Cyceron, Caen, France. 12 School of Psychological Science, The University of Western Australia, Perth, Western Australia, Australia. 13 Department Biomedical Engineering, McGill University, Montréal, Quebec, Canada. 14 Centre ÉPIC, Montreal Heart Institute, Montréal, Quebec, Canada. 15 School of Health, Concordia University, Montréal, Quebec, Canada. 16 Faculty of Dental Medicine and Oral Health Sciences, McGill University, Montreal, Quebec, Canada. 17 Department of Anesthesia, Faculty of Medicine and Health Sciences, McGill University, Montreal, Quebec, Canada. 18 Alan Edwards Center for Research on Pain, McGill University, Montreal, Quebec, Canada. 19 Department of Psychology, Toronto Metropolitan University, Toronto, Ontario, Canada. 20 Clinique interdisciplinaire de mémoire, CHU de Québec affilié à l'Université Laval, Québec, Quebec, Canada. 21 Division of Neurology, Department of Medicine, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, Quebec, Canada. 22 AI2D Center for AI and Data Science for Integrated Diagnostics, University of Pennsylvania, Philadelphia, Pennsylvania, USA. 23 Psychology Department, Université de Montréal, Montréal, Quebec, Canada. 24 Centre de Recherche de l'Institut Universitaire de Gériatrie de Montréal, Montréal, Quebec, Canada. 25 Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Mölndal, Sweden. 26 Clinical Neurochemistry Lab, Sahlgrenska University Hospital, Mölndal, Sweden. 27 Paris Brain Institute, ICM, Pitié-Salpêtrière Hospital, Sorbonne University, Paris, France. 28 Neurodegenerative Disorder Research Center, Division of Life Sciences and Medicine, and Department of Neurology, Institute on Aging and Brain Disorders, University of Science and Technology of China and First Affiliated Hospital of USTC, Hefei, Anhui, P.R. China. 29 Department of Neurodegenerative Disease, University College London Institute of Neurology, London, UK. 30 UK Dementia Research Institute at UCL, London, UK. 31 Hong Kong Center for Neurodegenerative Diseases, InnoHK, Hong Kong, China. 32 Wisconsin Alzheimer's Disease Research Center, University of Wisconsin School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin, USA. 33 Department of Physiology and Pharmacology, Université de Montréal, Montréal, Quebec, Canada. 34 Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University, Lund, Sweden. |
||||
Description: |
The PResymptomatic EValuation of Experimental or Novel Treatments for Alzheimer's Disease (PREVENT-AD) is an investigator-driven study that was created in 2011 and enrolled cognitively normal older adults with a family history of sporadic AD. Participants are deeply phenotyped and have now been followed annually for more than 12 years (median follow-up 8.0 years, SD 3.1). Multimodal magnetic resonance imaging (MRI), genetic, neurosensory, clinical, cerebrospinal fluid, and cognitive data collected until 2017 on 348 participants who agreed to open sharing with the neuroscience community were already available. We now share a new release including 6 years of additional follow-up cognitive data, and additional MRI follow-ups, clinical progression, new longitudinal behavioral and lifestyle measures (questionnaires, actigraphy), longitudinal AD plasma biomarkers, amyloid-beta and tau positron emission tomography (PET), magnetoencephalography, as well as neuroimaging analytic measures from all MRI modalities. We describe the PREVENT-AD study, the data shared with the global research community, as well as the model we created to sustain longitudinal follow-ups while also allowing new innovative data collection. HIGHLIGHTS: The PResymptomatic EValuation of Experimental or Novel Treatments for Alzheimer's Disease (PREVENT-AD) is a single-site longitudinal study that started in 2011 with annual follow-up data collection on individuals at risk of Alzheimer's disease who were all cognitively normal at enrolment. All 387 participants were enrolled between 2011 and 2017 and 306 (79%) of these participants were still in the study as of December 2023. While the PREVENT-AD dataset was not originally planned to be shared with the global research community, 348 participants retrospectively consented for their data to be shared with researchers worldwide. The first release of data was in 2019. We now share a second release that includes 6 years of additional follow-up visits, information on clinical progression and novel cognitive, behavioral, genetic, plasma and neuroimaging (amyloid and tau positron emission tomography [PET], magnetoencephalography [MEG], and new magnetic resonance imaging [MRI] sequences) data. It also includes analytic outputs for neuroimaging modalities. |
